Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: February 27, 2026, 9:19 pm
Author: Getaka|Social: XLinkedIn

Themis Medicare Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: February 27, 2026, 9:19 pm

Market Cap 788 Cr.
Current Price 85.8
Intrinsic Value₹23.69
High / Low 179/75.2
Stock P/E
Book Value 41.3
Dividend Yield0.58 %
ROCE10.4 %
ROE7.65 %
Face Value 1.00
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Themis Medicare Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Themis Medicare Ltd 788 Cr. 85.8 179/75.2 41.30.58 %10.4 %7.65 % 1.00
Anuh Pharma Ltd 776 Cr. 77.2 115/68.018.6 32.61.94 %17.2 %13.4 % 5.00
Fredun Pharmaceuticals Ltd 872 Cr. 1,624 1,999/63525.6 2940.04 %18.9 %15.8 % 10.0
Venus Remedies Ltd 900 Cr. 672 873/27811.8 4450.00 %11.1 %7.16 % 10.0
Wanbury Ltd 926 Cr. 266 330/15421.5 18.10.00 %36.7 %76.5 % 10.0
Industry Average20,545.80 Cr1,097.9755.88201.210.37%16.35%15.16%6.10

All Competitor Stocks of Themis Medicare Ltd

Quarterly Result

MetricSep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales 91.0088.7880.1096.65104.7882.5197.82122.99117.0193.8171.7097.5877.99
Expenses 69.6673.5169.6274.9192.3774.4688.5393.8199.8887.8479.40107.8081.09
Operating Profit 21.3415.2710.4821.7412.418.059.2929.1817.135.97-7.70-10.22-3.10
OPM % 23.45%17.20%13.08%22.49%11.84%9.76%9.50%23.73%14.64%6.36%-10.74%-10.47%-3.97%
Other Income 6.227.135.326.296.665.944.676.935.561.021.551.184.98
Interest 2.372.232.712.492.042.682.162.362.442.792.452.472.76
Depreciation 2.562.672.803.033.073.103.062.412.452.542.532.552.57
Profit before tax 22.6317.5010.2922.5113.968.218.7431.3417.801.66-11.13-14.06-3.45
Tax % 21.43%23.94%18.37%19.19%18.91%10.35%24.14%21.25%19.66%68.67%-13.12%1.14%4.64%
Net Profit 17.7813.318.4118.1911.327.376.6424.6814.290.52-9.66-14.22-3.62
EPS in Rs 1.931.450.911.981.230.800.722.681.550.06-1.05-1.54-0.39

Last Updated: December 28, 2025, 8:05 pm

Below is a detailed analysis of the quarterly data for Themis Medicare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Sales, as of Sep 2025, the value is 77.99 Cr.. The value appears to be declining and may need further review. It has decreased from 97.58 Cr. (Jun 2025) to 77.99 Cr., marking a decrease of 19.59 Cr..
  • For Expenses, as of Sep 2025, the value is 81.09 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 107.80 Cr. (Jun 2025) to 81.09 Cr., marking a decrease of 26.71 Cr..
  • For Operating Profit, as of Sep 2025, the value is -3.10 Cr.. The value appears strong and on an upward trend. It has increased from -10.22 Cr. (Jun 2025) to -3.10 Cr., marking an increase of 7.12 Cr..
  • For OPM %, as of Sep 2025, the value is -3.97%. The value appears strong and on an upward trend. It has increased from -10.47% (Jun 2025) to -3.97%, marking an increase of 6.50%.
  • For Other Income, as of Sep 2025, the value is 4.98 Cr.. The value appears strong and on an upward trend. It has increased from 1.18 Cr. (Jun 2025) to 4.98 Cr., marking an increase of 3.80 Cr..
  • For Interest, as of Sep 2025, the value is 2.76 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.47 Cr. (Jun 2025) to 2.76 Cr., marking an increase of 0.29 Cr..
  • For Depreciation, as of Sep 2025, the value is 2.57 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.55 Cr. (Jun 2025) to 2.57 Cr., marking an increase of 0.02 Cr..
  • For Profit before tax, as of Sep 2025, the value is -3.45 Cr.. The value appears strong and on an upward trend. It has increased from -14.06 Cr. (Jun 2025) to -3.45 Cr., marking an increase of 10.61 Cr..
  • For Tax %, as of Sep 2025, the value is 4.64%. The value appears to be increasing, which may not be favorable. It has increased from 1.14% (Jun 2025) to 4.64%, marking an increase of 3.50%.
  • For Net Profit, as of Sep 2025, the value is -3.62 Cr.. The value appears strong and on an upward trend. It has increased from -14.22 Cr. (Jun 2025) to -3.62 Cr., marking an increase of 10.60 Cr..
  • For EPS in Rs, as of Sep 2025, the value is -0.39. The value appears strong and on an upward trend. It has increased from -1.54 (Jun 2025) to -0.39, marking an increase of 1.15.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 4:46 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 195202232217210184202231395354382406337
Expenses 171184194184184181166181299287330356349
Operating Profit 24183833252364996675249-11
OPM % 12%9%16%15%12%1%18%21%24%19%13%12%-3%
Other Income 513346512131825241114
Interest 161512121212131391091010
Depreciation 9111277889910121010
Profit before tax 45171811-13274195735340-18
Tax % 32%-20%11%9%1%-15%8%14%23%22%19%25%
Net Profit 36161611-11253673574430-17
EPS in Rs 0.320.731.911.771.23-1.172.703.887.926.184.733.24-1.88
Dividend Payout % 28%25%9%-0%-0%-0%6%11%6%8%11%15%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)100.00%166.67%0.00%-31.25%-200.00%327.27%44.00%102.78%-21.92%-22.81%-31.82%
Change in YoY Net Profit Growth (%)0.00%66.67%-166.67%-31.25%-168.75%527.27%-283.27%58.78%-124.70%-0.89%-9.01%

Themis Medicare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:7%
5 Years:15%
3 Years:1%
TTM:-7%
Compounded Profit Growth
10 Years:17%
5 Years:4%
3 Years:-25%
TTM:-118%
Stock Price CAGR
10 Years:17%
5 Years:24%
3 Years:8%
1 Year:-59%
Return on Equity
10 Years:13%
5 Years:15%
3 Years:12%
Last Year:8%

Last Updated: September 5, 2025, 1:46 pm

Balance Sheet

Last Updated: December 4, 2025, 2:07 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 8899999999999
Reserves 485166143160149174209278330368393371
Borrowings 148140128828082100878092968396
Other Liabilities 7977735456746765618293102107
Total Liabilities 284277275289305314350371428514566588582
Fixed Assets 121122117124126123116133144162168172169
CWIP 12469228233333
Investments 45623242735455670899596
Other Assets 147146146133153162191191225279307318314
Total Assets 284277275289305314350371428514566588582

Below is a detailed analysis of the balance sheet data for Themis Medicare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
  • For Reserves, as of Sep 2025, the value is 371.00 Cr.. The value appears to be declining and may need further review. It has decreased from 393.00 Cr. (Mar 2025) to 371.00 Cr., marking a decrease of 22.00 Cr..
  • For Borrowings, as of Sep 2025, the value is 96.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 83.00 Cr. (Mar 2025) to 96.00 Cr., marking an increase of 13.00 Cr..
  • For Other Liabilities, as of Sep 2025, the value is 107.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 102.00 Cr. (Mar 2025) to 107.00 Cr., marking an increase of 5.00 Cr..
  • For Total Liabilities, as of Sep 2025, the value is 582.00 Cr.. The value appears to be improving (decreasing). It has decreased from 588.00 Cr. (Mar 2025) to 582.00 Cr., marking a decrease of 6.00 Cr..
  • For Fixed Assets, as of Sep 2025, the value is 169.00 Cr.. The value appears to be declining and may need further review. It has decreased from 172.00 Cr. (Mar 2025) to 169.00 Cr., marking a decrease of 3.00 Cr..
  • For CWIP, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
  • For Investments, as of Sep 2025, the value is 96.00 Cr.. The value appears strong and on an upward trend. It has increased from 95.00 Cr. (Mar 2025) to 96.00 Cr., marking an increase of 1.00 Cr..
  • For Other Assets, as of Sep 2025, the value is 314.00 Cr.. The value appears to be declining and may need further review. It has decreased from 318.00 Cr. (Mar 2025) to 314.00 Cr., marking a decrease of 4.00 Cr..
  • For Total Assets, as of Sep 2025, the value is 582.00 Cr.. The value appears to be declining and may need further review. It has decreased from 588.00 Cr. (Mar 2025) to 582.00 Cr., marking a decrease of 6.00 Cr..

Notably, the Reserves (371.00 Cr.) exceed the Borrowings (96.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 81926-281105734162235
Cash from Investing Activity + -7-6-7-4-0-4-5-16-16-24-16-12
Cash from Financing Activity + 2-18-135-9-107-26-180-9-26
Net Cash Flow 4-55-0-1-32161-8-3-3

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-124.00-122.00-90.00-49.00-55.00-80.00-64.00-38.0016.00-25.00-44.00-34.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 7482758112014518612393149170159
Inventory Days 280246243250253287315272150213188233
Days Payable 24023714516315618717114379123126142
Cash Conversion Cycle 11491172168216244330251164239232250
Working Capital Days -17-20-17-1619-1375172110116121
ROCE %10%9%15%13%10%-1%15%18%30%20%14%10%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 67.16%67.16%67.16%67.16%67.15%67.15%67.15%67.15%67.15%67.15%67.15%67.10%
FIIs 0.06%0.04%0.05%0.01%0.03%0.05%0.10%0.10%0.14%0.09%0.06%0.05%
DIIs 0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%
Public 32.78%32.80%32.77%32.82%32.81%32.79%32.74%32.75%32.70%32.75%32.77%32.84%
No. of Shareholders 5,9276,0076,97011,24411,29511,32214,27017,77317,88919,33522,49022,576

Shareholding Pattern Chart

No. of Shareholders

Themis Medicare Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Motilal Oswal S&P BSE Healthcare ETF 322 0.08 0.013222025-04-22 17:25:180%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 1.001.0010.0010.0010.00
Basic EPS (Rs.) 3.244.7361.8379.2238.86
Diluted EPS (Rs.) 3.244.7261.7379.0738.84
Cash EPS (Rs.) 3.684.0258.4477.1937.85
Book Value[Excl.RevalReserv]/Share (Rs.) 43.7441.03368.85312.48237.80
Book Value[Incl.RevalReserv]/Share (Rs.) 43.7441.03368.85312.48237.80
Revenue From Operations / Share (Rs.) 44.0641.48385.02428.91251.04
PBDIT / Share (Rs.) 5.846.1185.80111.0657.81
PBIT / Share (Rs.) 4.764.7874.39100.7548.50
PBT / Share (Rs.) 3.673.7664.0091.2234.67
Net Profit / Share (Rs.) 2.602.6947.0366.8928.54
NP After MI And SOA / Share (Rs.) 3.244.7361.8379.2238.86
PBDIT Margin (%) 13.2414.7322.2825.8923.02
PBIT Margin (%) 10.7911.5219.3223.4919.32
PBT Margin (%) 8.329.0716.6221.2613.81
Net Profit Margin (%) 5.896.4712.2115.5911.37
NP After MI And SOA Margin (%) 7.3511.4016.0518.4615.47
Return on Networth / Equity (%) 7.4111.5216.7625.3516.33
Return on Capital Employeed (%) 10.1310.6818.2629.1218.35
Return On Assets (%) 5.077.6811.0717.039.61
Long Term Debt / Equity (X) 0.040.070.080.080.10
Total Debt / Equity (X) 0.200.250.270.270.36
Asset Turnover Ratio (%) 0.700.700.751.050.67
Current Ratio (X) 1.951.901.901.961.45
Quick Ratio (X) 1.411.441.411.400.98
Inventory Turnover Ratio (X) 5.241.211.481.901.20
Dividend Payout Ratio (NP) (%) 15.4210.578.085.424.50
Dividend Payout Ratio (CP) (%) 11.578.256.824.803.63
Earning Retention Ratio (%) 84.5889.4391.9294.5895.50
Cash Earning Retention Ratio (%) 88.4391.7593.1895.2096.37
Interest Coverage Ratio (X) 5.356.008.2611.644.18
Interest Coverage Ratio (Post Tax) (X) 3.383.645.538.013.06
Enterprise Value (Cr.) 1419.922092.171146.53910.58312.04
EV / Net Operating Revenue (X) 3.505.483.242.311.35
EV / EBITDA (X) 26.4337.1914.528.915.87
MarketCap / Net Operating Revenue (X) 3.335.283.032.181.12
Retention Ratios (%) 84.5789.4291.9194.5795.49
Price / BV (X) 3.355.343.162.991.18
Price / Net Operating Revenue (X) 3.335.283.032.181.12
EarningsYield 0.020.020.050.080.13

After reviewing the key financial ratios for Themis Medicare Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 3.24. This value is below the healthy minimum of 5. It has decreased from 4.73 (Mar 24) to 3.24, marking a decrease of 1.49.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 3.24. This value is below the healthy minimum of 5. It has decreased from 4.72 (Mar 24) to 3.24, marking a decrease of 1.48.
  • For Cash EPS (Rs.), as of Mar 25, the value is 3.68. This value is within the healthy range. It has decreased from 4.02 (Mar 24) to 3.68, marking a decrease of 0.34.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 43.74. It has increased from 41.03 (Mar 24) to 43.74, marking an increase of 2.71.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 43.74. It has increased from 41.03 (Mar 24) to 43.74, marking an increase of 2.71.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 44.06. It has increased from 41.48 (Mar 24) to 44.06, marking an increase of 2.58.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 5.84. This value is within the healthy range. It has decreased from 6.11 (Mar 24) to 5.84, marking a decrease of 0.27.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 4.76. This value is within the healthy range. It has decreased from 4.78 (Mar 24) to 4.76, marking a decrease of 0.02.
  • For PBT / Share (Rs.), as of Mar 25, the value is 3.67. This value is within the healthy range. It has decreased from 3.76 (Mar 24) to 3.67, marking a decrease of 0.09.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 2.60. This value is within the healthy range. It has decreased from 2.69 (Mar 24) to 2.60, marking a decrease of 0.09.
  • For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.24. This value is within the healthy range. It has decreased from 4.73 (Mar 24) to 3.24, marking a decrease of 1.49.
  • For PBDIT Margin (%), as of Mar 25, the value is 13.24. This value is within the healthy range. It has decreased from 14.73 (Mar 24) to 13.24, marking a decrease of 1.49.
  • For PBIT Margin (%), as of Mar 25, the value is 10.79. This value is within the healthy range. It has decreased from 11.52 (Mar 24) to 10.79, marking a decrease of 0.73.
  • For PBT Margin (%), as of Mar 25, the value is 8.32. This value is below the healthy minimum of 10. It has decreased from 9.07 (Mar 24) to 8.32, marking a decrease of 0.75.
  • For Net Profit Margin (%), as of Mar 25, the value is 5.89. This value is within the healthy range. It has decreased from 6.47 (Mar 24) to 5.89, marking a decrease of 0.58.
  • For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.35. This value is below the healthy minimum of 8. It has decreased from 11.40 (Mar 24) to 7.35, marking a decrease of 4.05.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 7.41. This value is below the healthy minimum of 15. It has decreased from 11.52 (Mar 24) to 7.41, marking a decrease of 4.11.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 10.13. This value is within the healthy range. It has decreased from 10.68 (Mar 24) to 10.13, marking a decrease of 0.55.
  • For Return On Assets (%), as of Mar 25, the value is 5.07. This value is within the healthy range. It has decreased from 7.68 (Mar 24) to 5.07, marking a decrease of 2.61.
  • For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.07 (Mar 24) to 0.04, marking a decrease of 0.03.
  • For Total Debt / Equity (X), as of Mar 25, the value is 0.20. This value is within the healthy range. It has decreased from 0.25 (Mar 24) to 0.20, marking a decrease of 0.05.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 0.70. There is no change compared to the previous period (Mar 24) which recorded 0.70.
  • For Current Ratio (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.90 (Mar 24) to 1.95, marking an increase of 0.05.
  • For Quick Ratio (X), as of Mar 25, the value is 1.41. This value is within the healthy range. It has decreased from 1.44 (Mar 24) to 1.41, marking a decrease of 0.03.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.24. This value is within the healthy range. It has increased from 1.21 (Mar 24) to 5.24, marking an increase of 4.03.
  • For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 15.42. This value is below the healthy minimum of 20. It has increased from 10.57 (Mar 24) to 15.42, marking an increase of 4.85.
  • For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 11.57. This value is below the healthy minimum of 20. It has increased from 8.25 (Mar 24) to 11.57, marking an increase of 3.32.
  • For Earning Retention Ratio (%), as of Mar 25, the value is 84.58. This value exceeds the healthy maximum of 70. It has decreased from 89.43 (Mar 24) to 84.58, marking a decrease of 4.85.
  • For Cash Earning Retention Ratio (%), as of Mar 25, the value is 88.43. This value exceeds the healthy maximum of 70. It has decreased from 91.75 (Mar 24) to 88.43, marking a decrease of 3.32.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 5.35. This value is within the healthy range. It has decreased from 6.00 (Mar 24) to 5.35, marking a decrease of 0.65.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.38. This value is within the healthy range. It has decreased from 3.64 (Mar 24) to 3.38, marking a decrease of 0.26.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 1,419.92. It has decreased from 2,092.17 (Mar 24) to 1,419.92, marking a decrease of 672.25.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.50. This value exceeds the healthy maximum of 3. It has decreased from 5.48 (Mar 24) to 3.50, marking a decrease of 1.98.
  • For EV / EBITDA (X), as of Mar 25, the value is 26.43. This value exceeds the healthy maximum of 15. It has decreased from 37.19 (Mar 24) to 26.43, marking a decrease of 10.76.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 5.28 (Mar 24) to 3.33, marking a decrease of 1.95.
  • For Retention Ratios (%), as of Mar 25, the value is 84.57. This value exceeds the healthy maximum of 70. It has decreased from 89.42 (Mar 24) to 84.57, marking a decrease of 4.85.
  • For Price / BV (X), as of Mar 25, the value is 3.35. This value exceeds the healthy maximum of 3. It has decreased from 5.34 (Mar 24) to 3.35, marking a decrease of 1.99.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 5.28 (Mar 24) to 3.33, marking a decrease of 1.95.
  • For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Themis Medicare Ltd as of March 1, 2026 is: ₹38.13

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 1, 2026, Themis Medicare Ltd is Overvalued by 55.56% compared to the current share price ₹85.80

Default values used*: Default value of 15 for Stock P/E is used

Intrinsic Value of Themis Medicare Ltd as of March 1, 2026 is: ₹23.69

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 1, 2026, Themis Medicare Ltd is Overvalued by 72.39% compared to the current share price ₹85.80

Default values used*: Default value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: -37.87%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The company has higher reserves (210.77 cr) compared to borrowings (99.54 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (272.85 cr) and profit (27.15 cr) over the years.
  1. The stock has a low average ROCE of 13.58%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 37.92, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 205.92, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Themis Medicare Ltd:
    1. Net Profit Margin: 5.89%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 10.13% (Industry Average ROCE: 16.35%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 7.41% (Industry Average ROE: 15.16%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 3.38
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.41
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 0 (Industry average Stock P/E: 55.88)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.2
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Themis Medicare Ltd. is a Public Limited Listed company incorporated on 31/05/1969 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24110GJ1969PLC001590 and registration number is 001590. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 405.51 Cr. and Equity Capital is Rs. 9.20 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsPlot No.69-A, GIDC Industrial Estate, Valsad District Gujarat 396195Contact not found
Management
NamePosition Held
Dr. Dinesh S PatelChairman & Executive Director
Dr. Sachin D PatelManaging Director & CEO
Mr. Rajneesh K AnandNon Executive Director
Dr. Adam DemeterNon Executive Director
Ms. Manjul SandhuIndependent Director
Mr. Bhaskar V IyerIndependent Director
Mr. Nikunt K RavalIndependent Director
Ms. Neha ThakoreIndependent Director
Mr. Shishir V DalalIndependent Director
Mrs. Reena S PatelAlternate Director

FAQ

What is the intrinsic value of Themis Medicare Ltd?

Themis Medicare Ltd's intrinsic value (as of 01 March 2026) is ₹23.69 which is 72.39% lower the current market price of ₹85.80, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹788 Cr. market cap, FY2025-2026 high/low of ₹179/75.2, reserves of ₹371 Cr, and liabilities of ₹582 Cr.

What is the Market Cap of Themis Medicare Ltd?

The Market Cap of Themis Medicare Ltd is 788 Cr..

What is the current Stock Price of Themis Medicare Ltd as on 01 March 2026?

The current stock price of Themis Medicare Ltd as on 01 March 2026 is ₹85.8.

What is the High / Low of Themis Medicare Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Themis Medicare Ltd stocks is ₹179/75.2.

What is the Stock P/E of Themis Medicare Ltd?

The Stock P/E of Themis Medicare Ltd is .

What is the Book Value of Themis Medicare Ltd?

The Book Value of Themis Medicare Ltd is 41.3.

What is the Dividend Yield of Themis Medicare Ltd?

The Dividend Yield of Themis Medicare Ltd is 0.58 %.

What is the ROCE of Themis Medicare Ltd?

The ROCE of Themis Medicare Ltd is 10.4 %.

What is the ROE of Themis Medicare Ltd?

The ROE of Themis Medicare Ltd is 7.65 %.

What is the Face Value of Themis Medicare Ltd?

The Face Value of Themis Medicare Ltd is 1.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Themis Medicare Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports